Status:
ENROLLING_BY_INVITATION
A Randomized Trial of Early Detection of Clinically Significant Prostate Cancer (ProScreen)
Lead Sponsor:
Tampere University
Collaborating Sponsors:
Helsinki University Central Hospital
Tampere University Hospital
Conditions:
Prostate Cancer
Eligibility:
MALE
50-63 years
Phase:
NA
Brief Summary
A population-based randomised trial of prostate cancer screening will be carried out. A total of approximately 117,200 men aged 50-63 in Helsinki and Tampere are randomised to intervention (screening)...
Detailed Description
Frequent adverse effects have so far tipped the balance of benefits and harms against prostate cancer screening, and therefore the investigators will focus on employing the best possible means for red...
Eligibility Criteria
Inclusion
- 50-63-year-old men (age in 2018) residing in Tampere or Helsinki
Exclusion
- Prevalent prostate cancer
Key Trial Info
Start Date :
April 23 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2037
Estimated Enrollment :
17400 Patients enrolled
Trial Details
Trial ID
NCT03423303
Start Date
April 23 2018
End Date
December 31 2037
Last Update
April 17 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Helsinki University and Helsinki University Hospital
Helsinki, Finland
2
University of Tampere
Tampere, Finland